Search PubMed⌕ Search

Biomedical subjects

S Colagiuri

Publications and source records attributed to S Colagiuri.

61 records · Page 4Linked to original sources

Assessing effect of mixing insulins by glucose-clamp technique in subjects with diabetes mellitus.

The glucose-clamp technique was used to assess the effect on insulin activity of mixing clinically relevant doses of short- and longer-acting insulins in insulin-treated diabetic subjects. Mixtures of porcine regular and lente insulins resulted in a reduction in activity of the mixture compared with separate injection that was more apparent with premixing for 5 min before injecting than with premixing for 2 min. These findings were not explained by differences in volume of the injected insulin preparations. Mixing of porcine regular and bovine ultralente insulins for 2 min before injecting resulted in a reduced activity compared with separate injection. No difference in activity was obvious for porcine regular and NPH insulins given separately or premixed for 5 min. A reduction of activity during the 1st h after injection was observed when separate injection of one brand of these insulins (Velosulin or Insulatard) was compared with the manufactured mixture (Mixtard). These results indicate that premixing regular and NPH insulins in a 1-to-2 ratio does not alter the biological activity compared with separate administration of the insulins. However, the mixing of regular and insulin-zinc suspensions results in a loss of insulin activity, the magnitude of which depends on the time between mixing and injecting the insulin. The clinical significance of the effect of mixing on the efficacy of subcutaneous insulin therapy should be considered in the context that this is only one of many factors that may affect the activity of subcutaneously injected insulin.

Adult↗

Effectiveness of mass screening for diabetes mellitus using random capillary blood glucose measurements.

The results of 23 228 finger-prick capillary blood glucose tests (the taking of which was coordinated by the Diabetic Association of New South Wales) were reviewed. All non-diabetic persons (n = 860) with a blood glucose result of greater than or equal to 8.0 mmol/L were surveyed and 459 responded (53.4%). The responders were typical of the surveyed group with respect to age and capillary blood glucose level. Sixty-four new cases of diabetes were detected, representing 15.8% of the replies from persons who were not known to have diabetes and 0.28% of the total number of persons screened.

Age Factors↗

Metabolic profiles in diabetic subjects treated with human insulin (Novo) and porcine insulin.

Twenty-four-hour metabolic profiles were used to compare the efficacy of twice-daily injections of purified porcine and human Actrapid and Monotard insulins (Novo) in six insulin-treated diabetic subjects. Although both insulin regimens resulted in similar plasma glucose profiles, values were lower during the night with porcine insulin treatment. These differences in plasma glucose response may represent an increased effectiveness of porcine insulin. Alternatively, evaluation of the plasma glucose profiles by the mean of the daily differences suggests that inherent day-to-day variations in diabetic control could explain the differences observed. Also, the potency of the porcine insulin used was greater than that of the human insulin and may have contributed to the differences in glucose response. No differences were observed in pyruvate, lactate, total ketones, and insulin profiles over the 24-h period. No adverse reactions to human insulin occurred.

Adult↗

Intravenous immunoglobulin therapy for autoimmune diabetes mellitus.

OBJECTIVE: A variety of immune therapies have been used in an attempt to reduce the immune destruction of the insulin secreting beta cells which results in insulin dependent diabetes mellitus (IDDM). This study investigated the use of intravenous gammaglobulin therapy (IVIG) in children and adults with IDDM who participated in a two-year randomised controlled trial which also examined the effect of transfer factor in altering the natural course of IDDM. METHODS: Treatment was administered every two months for the duration of the study. IVIG was given in a dose of 2 g/ kg body weight in divided doses over two days. The other two groups received an intramuscular injection-the control group received normal saline and the transfer factor group received 1 i.u. of transfer factor. Remission rates, beta cell function and treatment side effects were assessed. RESULTS: Compared with the control group, IVIG therapy given every 2 months for 2 years, did not result in an increased number of complete remissions or differences in insulin dose, diabetes control or endogenous insulin secretion assessed as fasting and stimulated C-peptide responses to glucagon and a meal. IVIG therapy was associated with significant side effects. CONCLUSION: It is unlikely that IVIG therapy will be a viable option for immunotherapy in IDDM.

Adolescent↗